SOPRANO

A trial of stereotactic body radiotherapy (SBRT) with niraparib in people with ovarian cancer.

Status: Enrolling participants

What is the study about?

SOPRANO investigates targeted radiotherapy either on its own or followed by a drug called niraparib for certain types of advanced ovarian cancer.

People with ovarian cancers are often treated with PARP inhibitors, a type of drug which works by blocking the ability of cancer cells to repair themselves. These cancer cells become too damaged to survive and they die.

Despite treatment with PARP inhibitors, cancer can grow or spread in small areas around the body. These small areas of cancer can be treated with stereotactic radiotherapy (SBRT). SBRT uses lots of radiation beams to target the cancer, reducing radiation to surrounding areas of the body. This allows very small areas of cancer to be precisely treated. SBRT may work even better when followed by another course of a PARP inhibitor.

SOPRANO will investigate whether giving SBRT on its own or followed by the PARP inhibitor niraparib will prevent certain types of advanced ovarian cancer from getting worse.

Who is included in the study?

42 participants across approximately 8 NHS hospitals in the UK will take part in the study.

SOPRANO includes people with certain types of advanced ovarian cancer, which has grown in small areas throughout the body during or after treatment with a PARP inhibitor. People with the following types of cancer may join the trial:

Epithelial ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer

Your doctor will review your test results and medical history to find out if you are eligible to take part.

Forty-two people will be included from up to six NHS hospitals across the UK.

What are the study treatments?

Participants will choose one of two treatment options with their clinician:

SBRT followed by niraparib
SBRT on its own

Up to 21 patients will join each treatment group.

SBRT will be given to all the small areas of cancer growth during 3 to 8 hospital visits over 5 to 19 days, depending on the areas being treated. After SBRT finishes, people in the SBRT followed by niraparib group will take niraparib tablets once a day.

Participants have regular check ups during and after their treatment and we collect information about how they are getting on until the study is completed.

Where is the trial avaliable?

SOPRANO is a UK-wide clinical study involving approximatly 8 NHS hospitals and cancer centres.

The study is currently open at:

The Royal Marsden (Sutton and London)
The Christie
University College Hospital
St James's University Hospital, Leeds
Western General Hospital, Edinburgh
Leicester Royal Infirmary

Not all hospitals are able to offer this study. Whether you can take part depends on if your local cancer centre is involved or if you are willing to travel to participate.

If your local hospital is not taking part in the SOPRANO study, your doctor may be able to:

Check is a nearby hospital is offering the SOPRANO study, or
Refer you to a centre that is taking part, if it is suitable for you.

Taking Part in the SOPRANO Study

If you are interested in taking part in the SOPRANO study, we recommend discussing your treatment options with your oncologist. They can advise whether the SOPRANO study or another clinical trial may be suitable for you. Participation may involve referral to one of the hospitals currently running the study, and your oncologist can support you through this process and answer any questions you may have.

Further information for participants

Lay Summary

Further information for healthcare professionals

Trial Schema

View a plain English summary from Cancer Research UK

Contact details and regulatory information

Chief Investigator: Professor Susana Banerjee, The Royal Marsden NHS Foundation Trust

SBRT Lead: Dr Alexandra Taylor, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific/Methodology Lead: Dr Nuria Porta

Trial management contact: [email protected]

Sponsor: The Institute of Cancer Research

Funding: GlaxoSmithKline (GSK)